Clinical trial
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With…
NCT00193219 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193219 |
|---|---|
| Title | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer |
| Official title | A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Cetuximab, 5-fluorouracil, Leucovorin, Oxaliplatin |
| Enrollment | 36 |
| Start date | Jul 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 11, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: